Readystate Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Readystate Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-34,100	Closed	-$1.37M	–	912
2026 Q1	$1.37M	Buy	+34,100	New	+$735K	0.06%	201
2025 Q4	–	Sell	-241,977	Closed	-$5.48M	–	392
2025 Q3	$5.48M	Buy	+241,977	New	+$5.64M	0.23%	93
2025 Q1	–	Sell	-35,561	Closed	-$1.13M	–	603
2024 Q4	$1.13M	Buy	+35,561	New	+$1.07M	0.03%	384
2024 Q2	–	Sell	-5,438	Closed	-$320K	–	708
2024 Q1	$320K	Buy	+5,438	New	+$347K	﹤0.01%	843

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Readystate Asset Management's APLS Position: Q2 2026 in Review

Readystate Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 34,100 shares — an estimated $1.37M sold.

Readystate Asset Management first reported a position in APLS in Q1 2024 and held it in 4 quarters. The position peaked at $5.48M in Q3 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Readystate Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Readystate Asset Management sold 34,100 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.37M.
Readystate Asset Management first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 4 quarters.
Readystate Asset Management's Apellis Pharmaceuticals position peaked at $5.48M in Q3 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Readystate Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.